http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#Head http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#assertion http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#provenance http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#pubinfo http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#assertion http://purl.obolibrary.org/obo/DOID_769 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_769 http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00997 http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#association http://www.w3.org/2000/01/rdf-schema#label doxorubicin hydrochloride hcl for injection is an anthracycline topoisomerase ii inhibitor indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer 1 1 for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma non hodgkin lymphoma metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcomas metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma 1 2 doxorubicin hcl for injection is indicated as a component of multi agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer see clinical studies 14 doxorubicin hcl for injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma non hodgkin lymphoma nhl metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00997 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#provenance http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#pubinfo http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#sig http://purl.org/nanopub/x/hasSignature O2gIXw5daV30FBXkXjAIjczS06vw+AxDpqjf8YZFv2nCj4x/Uyh2JXv2Zw14kEhetAxSH0KC+hIb/9zJ7/SKw5N+45UrQ8RUzCM0OzDx0NEzK42BpFiVl4MmAG6vVL6AOAejF18dgOLuVOo843gZAvkMER0eba6t8zegHDFjNs0= http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64 http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64 http://purl.org/dc/terms/created 2021-06-29T08:29:31.166+02:00 http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAQLYti9yTsIbAP3wGgAt3Snw9ixWbku3Q4c2hGGKir64 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs